Clinical trials
SLE (Systemic Lupus) clinical trials
Below are recruiting sle (systemic lupus) clinical trials, each written for real people, not researchers. We’re tracking 215 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06394063Recruiting
Telitacicept to prevent lupus flares
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
ShanghaiAges 18–70 - NCT07611747RecruitingPhase 4
Ultrasound Screening to Prevent Heart Disease in Rheumatic Patients
This study tests whether using ultrasound to look at arteries in the neck can help prevent heart attacks and strokes in people with inflammatory joint diseases like rheumatoid arthritis or lupus. Researchers will use the results to guide treatment decisions.
Alicante, AlicanteAges 50 years+ - NCT07517536Enrolling by invitation
CHT105 treatment for hard-to-treat lupus kidney disease
This study tests a new medicine called CHT105 for lupus patients whose kidney disease hasn't improved with standard treatments. The medicine targets specific immune cells that may be driving the kidney damage.
Nanjing, JiangsuAges 18–65 - NCT07470151Recruiting
Study of EVM18001 for hard-to-treat autoimmune diseases
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Wuhan, HubeiAges 18–70 - NCT07174843RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06897930RecruitingPhase 1/Phase 2
Testing a new drug for adults with lupus
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
San Francisco, CaliforniaAges 18–70 - NCT06647069RecruitingPhase 1
Testing a new drug for lupus and rheumatoid arthritis
This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.
Melbourne, VictoriaAges 18–75 - NCT06182969RecruitingPhase 1/Phase 2
APG-2575 for mild to moderate lupus
This trial tests an experimental drug called APG-2575 for people with mild to moderate lupus. It aims to see if the drug can help control lupus activity and improve symptoms.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT05858684RecruitingEarly Phase 1
CAR-T therapy for hard-to-control lupus
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT03543839RecruitingPhase 4
Belimumab for early lupus activity in the first two years
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Manhasset, New YorkAges 18 years+ - NCT07330245Recruiting
Study of anifrolumab for lupus patients needing treatment
This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.
Monserrato, CAAges Any age - NCT06685042RecruitingPhase 1/Phase 2
CAR T-cell therapy for severe autoimmune diseases
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
Rome, LazioAges 18–65 - NCT07629596RecruitingEarly Phase 1
mRNA CAR-T therapy for severe lupus or autoimmune anemia
This early-stage trial tests a new mRNA-based therapy called Arnovie101 that trains your immune cells to fight lupus (SLE) or autoimmune hemolytic anemia (AIHA) that haven't improved with standard treatments. The therapy may help reduce disease activity and symptoms.
Beijing, Beijing MunicipalityAges 18–60 - NCT07219563RecruitingPhase 1
Alnuctamab for hard-to-treat lupus (LATTE Study)
This trial tests a new drug called alnuctamab for people with lupus (SLE) that hasn't responded to multiple standard treatments. It aims to see if targeting certain immune cells can reduce lupus activity.
New York, New YorkAges 18–60 - NCT06711146RecruitingEarly Phase 1
CAR T-cell therapy for active lupus
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
Hangzhou, ZhejiangAges 18 years+ - NCT06916806RecruitingPhase 1
Study of AZD5492 for lupus, myositis, or rheumatoid arthritis
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
Anniston, AlabamaAges 18–70 - NCT07148115Recruiting
Pregnancies before lupus diagnosis
This trial studies women who had at least one pregnancy before being diagnosed with lupus. It aims to understand how lupus may have affected those pregnancies.
Aïn Taya, Algiers ProvinceAges 18–55 - NCT06347718RecruitingPhase 1/Phase 2
Car-T cells for autoimmune disease
This study tests a type of immunotherapy called CAR-T cells for people with certain autoimmune diseases like lupus, scleroderma, or myositis. It aims to see if this treatment can help when standard medicines haven't worked well enough.
Erlangen, BavariaAges 18 years+ - NCT04976465RecruitingPhase 1
SLE Treatment During Pregnancy Study
This Phase 1 study looks at a treatment plan for people with systemic lupus (SLE) during pregnancy and tracks health outcomes for mother and baby. It may help doctors learn how to manage SLE safely in pregnancy and what results to expect.
Jinan, ShandongAges 20–45 - NCT07636044Recruiting
Shingles Vaccine Response in Lupus Patients
This study tests how well the shingles vaccine (Shingrix) works in people with lupus who take immune-suppressing medications. Researchers want to understand if the vaccine provides good protection in lupus patients, since their immune systems work differently.
SeoulAges 50 years+ - NCT07201558RecruitingPhase 1
Surovatamig safety study for rheumatoid arthritis or lupus
This trial tests surovatamig, a new experimental treatment, to see if it's safe and how the body processes it in adults with moderate-to-severe rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). It may be an option if you've tried other biologic or targeted therapies without success.
Birmingham, AlabamaAges 18–65 - NCT06458075Recruiting
Improving communication and medication adherence in lupus
This study tests whether helping lupus patients and their doctors communicate better leads to taking medications more consistently. Participants will have their doctor visits recorded and use a phone app to track their medicines.
Durham, North CarolinaAges 18–90 - NCT05559671RecruitingPhase 4
Shingles vaccine safety study for people with lupus
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
New York, New YorkAges 18–90
Hear when a new SLE (Systemic Lupus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sle (systemic lupus)?
- Yes. Clin2 currently lists 215 recruiting sle (systemic lupus) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sle (systemic lupus) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sle (systemic lupus) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.